Grifols B : Positive p. IIIb results for its paediatric fibrin sealant to treat surgical bleeding
>All primary and secondary endpoints met, while displaying a positive safety and tolerability profile - The company has announced that its plasma-protein based fibrin sealant for controlling surgical bleeding obtained positive top-line results from a phase IIIb clinical trial in paediatric patients. Having met all primary and secondary endpoints, the study is expected to facilitate regulatory approval to expand the use of the fibrin sealant-based biosurgery treatment,...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.